Patients who relapse or become refractory after successful induction therapy should receive rituximab maintenance therapy, which improves overall survival. Medscape Medical News
There was a 73% reduction in fracture risk with teriparatide in postmenopausal women with severe osteoporosis, with risk beginning to drop after the first 6 months of treatment. Medscape Medical News
The results of a pivotal prostate cancer trial, now published, show that the addition of radiotherapy to androgen-deprivation therapy (ADT) halves the risk of dying from the disease. Medscape Medical News
